Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.38 |
| ▸ | LAP3 | P28838 | 3/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23827953 | 0.85 | FDPS (0.46) | FDPSPTPN1TSHRPTPRCSMN1; SMN2 | |
| SCHEMBL11120024 | 0.81 | FDPS (0.55) | FDPSPTPN1TSHRPTPRCPDPK1 | |
| SCHEMBL11535809 | 0.76 | FDPS (0.50) | FDPSPTPN1TSHRPTPRCPDPK1 | |
| SCHEMBL21121849 | 0.75 | FDPS (0.49) | FDPSPTPN1TSHRPDPK1MTOR | |
| SCHEMBL29182980 | 0.75 | FDPS (0.62) | FDPSPTPN1TSHRPTPRCSMN1; SMN2 | |
| SCHEMBL27514707 | 0.74 | FDPS (0.51) | FDPSPTPN1TSHRPTPRCPDPK1 | |
| SCHEMBL3728040 | 0.74 | FDPS (0.47) | FDPSPTPN1TSHRPTPRCPDPK1 | |
| SCHEMBL11318157 | 0.74 | FDPS (0.47) | FDPSPTPN1TSHRPTPRCPDPK1 | |
| SCHEMBL29127601 | 0.71 | PTPN1 (0.47) | FDPSPTPN1TSHRSRCCYP1A2 | |
| SCHEMBL29049152 | 0.71 | PTPN1 (0.47) | FDPSPTPN1TSHRSRCCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055373-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260035394-A1 | 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4644394-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4106876-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12404289-B2 | 1′-cyano nucleoside analogs and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| WO-2025101944-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A | Plexium, Inc. (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20250002513-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-01-02 | — | — | US | disclosed |
| US-20240336583-A1 | BENZO-RING-CONTAINING DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHUJING BIOPHARMA CO., LTD (CN) | 2024-10-10 | — | — | US | disclosed |
| US-20240287109-A1 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| US-12030903-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-7244718-B2 | Water soluble prodrugs of hindered alcohols | UNIVERSITY OF KANSAS (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1683803-A1 | Water soluble prodrugs of hindered alcohols or phenols | THE UNIVERSITY OF KANSAS (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1102776-B1 | WATER SOLUBLE PRODRUGS OF HINDERED PHENOLS | UNIV KANSAS (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20050090431-A1 | Water soluble prodrugs of hindered alcohols | UNIVERSITY OF KANSAS (US) | 2005-04-28 | — | — | US | disclosed |
| US-6872838-B2 | Water soluble prodrugs of hindered alcohols | UNIVERSITY OF KANSAS (US) | 2005-03-29 | — | — | US | disclosed |
| US-20030176324-A1 | Water soluble prodrugs of hindered alcohols | UNIVERSITY OF KANSAS | 2003-09-18 | — | — | US | disclosed |
| US-6451776-B2 | A WATER SOLUBLE PHOPHONOOXYMETHYL ETHERS OF HINDERED ALCOHOL AND PHENOL CONTAINING PHARMECEUTICALS, SUCH AS CAMPTOTHECIN, PROPOFOL, ETOPOSIDE, VITAMIN E, AND CYCLOSPROIN A | UNIVERSITY OF KANSAS | 2002-09-17 | — | — | US | disclosed |
| US-20010025035-A1 | Water soluble prodrugs of hindered alcohols | UNIVERSITY OF KANSAS | 2001-09-27 | — | — | US | disclosed |
| EP-1102776-A1 | WATER SOLUBLE PRODRUGS OF HINDERED ALCOHOLS OR PHENOLS | THE UNIVERSITY OF KANSAS (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000008033-A1 | WATER SOLUBLE PRODRUGS OF HINDERED ALCOHOLS OR PHENOLS | THE UNIVERSITY OF KANSAS (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176324-A1 | Water soluble prodrugs of hindered alcohols | ADH1A, ADH5, ADH1C | FDPS 1115/4885PTPN1 2400/4885TSHR 1482/4885 |
| US-12030903-B2 | Antiviral compounds | EIF2AK2, MAVS, DUT | FDPS 427/4885PTPN1 3204/4885TSHR 4684/4885 |
| US-20050090431-A1 | Water soluble prodrugs of hindered alcohols | ADH1A, ADH5, ADH1C | FDPS 1115/4885PTPN1 2400/4885TSHR 1482/4885 |
| US-20240336583-A1 | BENZO-RING-CONTAINING DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | GABRA1, GABRA4, GABRA5 | FDPS 555/4885PTPN1 4569/4885TSHR 2212/4885 |
| US-20240287109-A1 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | TYMP, PNP, DUT | FDPS 540/4885PTPN1 2930/4885TSHR 4786/4885 |
| US-20250002513-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, DUT | FDPS 427/4885PTPN1 3204/4885TSHR 4684/4885 |
| US-12404289-B2 | 1′-cyano nucleoside analogs and uses thereof | TYMP, PNP, DUT | FDPS 597/4885PTPN1 2956/4885TSHR 4765/4885 |
| US-20010025035-A1 | Water soluble prodrugs of hindered alcohols | ADH1A, ADH5, ADH1C | FDPS 1115/4885PTPN1 2400/4885TSHR 1482/4885 |
| US-20260035394-A1 | 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | PNP, SLC28A1, SLC29A1 | FDPS 2155/4885PTPN1 545/4885TSHR 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.